|
L&C BIO is a biotechnology company that manufactures and sells human tissue grafts, tissue-based medical devices, cosmeceuticals, and pharmaceuticals. The company's primary revenue is generated from human tissue grafts, which include products for bone, cartilage, fascia, skin, amnion, ligaments, tendons, heart valves, blood vessels, nerves, and pericardium. Its flagship product, MegaDerm, is an acellular dermal matrix used for breast reconstruction following cancer treatment. L&C BIO also develops tissue-based medical devices by cross-linking human tissue with biopolymers, targeting markets in China, Southeast Asia, Latin America, and the Middle East where tissue laws are less established. The company operates in the cosmeceutical sector, producing functional cosmetics and health functional foods, and provides Contract Research Organization (CRO) services for cosmetic and pharmaceutical testing through its subsidiary Global Medical Research Center. Additionally, L&C BIO engages in pharmaceutical business activities utilizing its existing surgical network. Key products under development include MegaCarti for osteoarthritis, MegaShield as an anti-adhesion barrier, and MegaNerve Prime for nerve grafting. The company serves domestic hospitals, clinics, and burn centers in South Korea, while expanding internationally through local partners and academic collaborations. Subsidiaries include L&C Medical, L&C Care, and L&C China, which support its operations in medical device distribution, healthcare services, and the Chinese market. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Medical Devices | Homepage lncbio.co.kr |
| Sector Healthcare | IR page — | |
|
Tags
human tissue grafts, acellular dermal matrix, regenerative medicine, cosmeceuticals, cosmetic cro, pharmaceuticals, biopolymers, nerve grafts, anti-adhesion barriers, breast reconstruction, MegaDerm, MegaCarti, MegaShield, MegaNerve Prime, MegaDBM S, MegaCure, MegaAdipo ECM, Mega3DEar, MegaCartilage-E, MegaCare W, ZAG peptide, MegaPlug, MegaFill Putty, TendonFill, Sheet type MegaFill, MegaDerm Soft FD type, Pocket type ADM, ES.Fill, ES.Stat, Re2O, BytheDoctor Ato, MF3, Global Medical Research Center, L&C Medical, L&C Care, L&C China
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | ₩ 2.605T |
| Market cap (USD) | $ 1.917B |
| P/E | -17.30 |
| PEG | — |
| P/BV | 8.02 |
| P/S | 22.42 |
| P/OCF | 99.79 |
| P/FCF | -672.25 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -57.3% |
| ROI | -69.7% |
| ROIC | 1.7% |
| Profit margin | -161.7% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | No |
| Revenue up 3y | Yes |
| Revenue up 5y | Yes |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | No |
| Buying back stock | — |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | — |
| Quality score | -43.8% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 85.476B | 72.093B | 68.87B | 52.572B | 45.677B | 32.973B | 29.152B | 21.241B | 17.901B | 11.822B |
| Net profit | -138.175B | 141.064B | 48.361B | 4.544B | 13.814B | 10.813B | 7.25B | 5.208B | 3.753B | 1.981B |
| Free cash flow | -3.245B | -13.282B | -36.636B | -43.607B | 655.691M | 4.403B | 4.473B | -893.381M | 3.533B | -816.262M |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (KRW) | 4.35B | 6.01B | 7.5B | 10.1B | 9.33B | 14.8B | 16.8B | 22.6B | 54.2B | 25.7B |
| ↳ YoY growth | +38.0% | +24.8% | +35.3% | -8.0% | +58.8% | +13.3% | +34.8% | +139.4% | -52.5% | |
| ↳ 5y CAGR | +27.8% | +22.8% | +24.7% | +39.8% | +22.5% | |||||
| Borrowings, current (KRW) | 542M | 463M | 0.00 | — | — | 126M | 9.67B | 72.2B | 98.1B | 48.5B |
| Borrowings, non-current (KRW) | 401M | 0.00 | 1B | 1B | 9.62B | 5.45B | 59.8B | 541M | 20.1B | 4.02B |
| Bonds payable (KRW) | — | — | — | — | 8.62B | 4.57B | 59.1B | 63.8B | 66.4B | 48.5B |
| Cash and deposits (KRW) | 383M | 3.12B | 21.6B | 12.8B | 22.3B | 17.4B | 6.59B | 14.9B | 18.3B | 30.9B |
| Intangible assets (KRW) | 109M | 92.8M | 86.6M | 218M | 215M | 1.15B | 3.58B | 1.46B | 199B | 128B |
| Net debt (borrowings + leases - cash) (KRW) | 560M | -2.66B | -20.6B | -11.8B | -12.6B | -11.8B | 62.9B | 57.8B | 99.9B | 21.7B |
| Cash flow detail | ||||||||||
| Operating cash flow (KRW) | -185M | 3.82B | 3.85B | 6.43B | 7.42B | 10.9B | -6.08B | -12.1B | -8.57B | 12.6B |
| Purchases of property, plant and equipment (KRW) | -631M | -285M | -4.74B | -1.96B | -3.02B | -10.3B | -37.5B | -24.5B | -4.72B | -15.8B |
| Purchases of intangible assets (KRW) | -84.9M | -13.4M | -28.7M | -51.5M | -38.5M | -1.18B | -172M | -481M | -634M | -1.23B |
| Dividends paid (cash effect) (KRW) | — | — | — | — | -729M | -1.08B | -1.11B | -1.11B | -2.27B | -1.12B |
| Share buybacks (cash effect) (KRW) | — | — | — | — | -12.7B | -2.05B | — | -840M | 0.00 | -10B |
| Interest paid (cash effect) (KRW) | -43.8M | -18.2M | -17.5M | -16.4M | -15.1M | -23M | -159M | -531M | -498M | -1.86B |
| Income taxes paid (cash effect) (KRW) | -59.9M | -505M | -1.05B | -1.32B | -1.59B | 514M | -1.25B | -1.22B | -14.9B | 283M |
| Free cash flow (OCF - PPE - intangibles) (KRW) | -901M | 3.52B | -922M | 4.42B | 4.36B | -521M | -43.8B | -37.1B | -13.9B | -4.47B |
| Income detail | ||||||||||
| Total comprehensive income (KRW) | 2.02B | 3.89B | 5.1B | 8.3B | 11.9B | 16.6B | 6.97B | 46.1B | 139B | -138B |
| Comprehensive income to owners (KRW) | 2.02B | 3.89B | 5.21B | 7.1B | 10.6B | 14.8B | 5.8B | 46B | 139B | -138B |
| Reported | Apr 1, 2019 | Apr 1, 2019 | Apr 1, 2019 | Mar 30, 2020 | Mar 31, 2021 | Mar 20, 2024 | Mar 20, 2024 | Mar 20, 2024 | Mar 24, 2026 | Mar 24, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpDisclosures filed with DART (material events and exchange disclosures), newest first, headlines as filed in Korean. The link opens the filing on DART. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding L&C BIO
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
